NCCN Guidelines Insights: Primary Cutaneous Lymphomas, Version 2.2020-Reference-Cited by-同舟云学术

NCCN Guidelines Insights: Primary Cutaneous Lymphomas, Version 2.2020

Published:2020-05 Issue:5 Volume:18 Page:522-536
ISSN:1540-1405
Container-title:Journal of the National Comprehensive Cancer Network
language:
Short-container-title:

Author:

Mehta-Shah Neha¹,Horwitz Steven M.²,Ansell Stephen³,Ai Weiyun Z.⁴,Barnes Jeffrey⁵,Barta Stefan K.⁶,Clemens Mark W.⁷,Dogan Ahmet²,Fisher Kristopher⁸,Goodman Aaron M.⁹,Goyal Gaurav¹⁰,Guitart Joan¹¹,Halwani Ahmad¹²,Haverkos Bradley M.¹³,Hoppe Richard T.¹⁴,Jacobsen Eric¹⁵,Jagadeesh Deepa¹⁶,Lunning Matthew A.¹⁷,Mehta Amitkumar¹⁰,Olsen Elise A.¹⁸,Pro Barbara¹¹,Rajguru Saurabh A.¹⁹,Shanbhag Satish²⁰,Shaver Aaron²¹,Shustov Andrei²²,Sokol Lubomir²³,Torka Pallawi²⁴,Torres-Cabala Carlos⁷,Wilcox Ryan²⁵,William Basem M.²⁶,Zain Jasmine²⁷,Dwyer Mary A.²⁸,Sundar Hema²⁸,Kim Youn H.¹⁴

Affiliation:

1. 1Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine;

2. 2Memorial Sloan Kettering Cancer Center;

3. 3Mayo Clinic Cancer Center;

4. 4UCSF Helen Diller Family Comprehensive Cancer Center;

5. 5Massachusetts General Hospital Cancer Center;

6. 6Abramson Cancer Center at the University of Pennsylvania;

7. 7The University of Texas MD Anderson Cancer Center;

8. 8St. Jude Children's Research Hospital/The University of Tennessee Health Science Center;

9. 9UC San Diego Moores Cancer Center;

10. 10O'Neal Comprehensive Cancer Center at UAB;

11. 11Robert H. Lurie Comprehensive Cancer Center of Northwestern University;

12. 12Huntsman Cancer Institute at the University of Utah;

13. 13University of Colorado Cancer Center;

14. 14Stanford Cancer Institute;

15. 15Dana-Farber/Brigham and Women's Cancer Center;

16. 16Case Comprehensive Cancer Center/University Hospitals Seidman Cancer Center and Cleveland Clinic Taussig Cancer Institute;

17. 17Fred & Pamela Buffett Cancer Center;

18. 18Duke Cancer Institute;

19. 19University of Wisconsin Carbone Cancer Center;

20. 20The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins;

21. 21Vanderbilt-Ingram Cancer Center;

22. 22Fred Hutchinson Cancer Research Center/Seattle Cancer Care Alliance;

23. 23Moffitt Cancer Center;

24. 24Roswell Park Comprehensive Cancer Center;

25. 25University of Michigan Rogel Cancer Center;

26. 26The Ohio State University Comprehensive Cancer Center – James Cancer Hospital and Solove Research Institute;

27. 27City of Hope National Medical Center; and

28. 28National Comprehensive Cancer Network.

Abstract

Mycosis fungoides (MF) is the most common subtype of cutaneous T-cell lymphoma (CTCL), and Sézary syndrome (SS) is a rare erythrodermic and leukemic subtype of CTCL characterized by significant blood involvement. Although early-stage disease can be effectively treated predominantly with skin-directed therapies, systemic therapy is often necessary for the treatment of advanced-stage disease. Systemic therapy options have evolved in recent years with the approval of novel agents such as romidepsin, brentuximab vedotin, and mogamulizumab. These NCCN Guidelines Insights discuss the diagnosis and management of MF and SS (with a focus on systemic therapy).

Publisher

Harborside Press, LLC

Subject

Oncology

Link

https://jnccn.org/downloadpdf/journals/jnccn/18/5/article-p522.xml

Cited by 64 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. SOHO State-of-the-Art Updates and Next Questions: Treatment for Newly Diagnosed Peripheral T-Cell Lymphomas;Clinical Lymphoma Myeloma and Leukemia;2024-02

2. Linfoma cutáneo primario anaplásico de células grandes CD30 + con compromiso multifocal de la cara;Piel;2023-12

3. Immunopathogenesis of cutaneous T-cell lymphoma in skin of color patients part 2: Sézary syndrome;Clinical Immunology Communications;2023-12

4. Clinical characteristics, initial treatment, and prognosis of mycosis fungoides and Sézary syndrome: A retrospective, single-center study at the Centre Hospitalier Universitaire of Quebec;Annales de Dermatologie et de Vénéréologie;2023-12

5. HyBryte™ use in early-stage cutaneous T-cell lymphoma;Frontiers in Drug Discovery;2023-11-27